bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
bluebird bio, Inc. (Nasdaq: BLUE) today announced interim data published in the New England Journal of Medicine (NEJM) from two separate two-year clinical studies investigating the potential for LentiGlobin™ gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT). Both studies, Northstar (HGB-204), which recently was completed, and HGB-205, which is ongoing, are evaluating the safety and efficacy of one-time treatment with LentiGlobin gene therapy and the interim results showed that a majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer remained free from transfusions.
Interim results also showed that all but one patient with a non-β0/β0 genotype (12 of 13 patients) stopped receiving regular red blood cell (RBC) transfusions, with a median time since last transfusion of 27 months. In the nine patients with a β0/β0 genotype or similar severity, median transfusion volume decreased by 73 percent, and RBC transfusions were stopped in three patients. Treatment with LentiGlobin requires an autologous stem cell transplant. The safety profile of LentiGlobin has been consistent with myeloablative conditioning with the chemotherapy agent busulfan.
“These interim data demonstrate the potential of LentiGlobin gene therapy to address the underlying genetic cause of TDT and increase production of functional red blood cells,” said Dave Davidson, M.D., chief medical officer, bluebird bio. “Nearly all patients in the two studies with a non-β0/β0 genotype achieved freedom from chronic blood transfusions and, importantly, several of these patients reached normal or near-normal total hemoglobin levels and sustained those levels throughout the interim study period. We hope the refined manufacturing process implemented in our ongoing pivotal trials of LentiGlobin will translate into further normalization of total hemoglobin levels across genotypes.”
“We look forward to our first filing in the European Union (EU) this year and continue to work closely with investigators and regulatory authorities to complete our trials and bring this important treatment option to patients as soon as possible,” said Davidson.
Transfusion-dependent thalassemia is a severe genetic disease characterized by reduced or absent hemoglobin production that results in severe anemia and ineffective red blood cell production. People with TDT need regular blood transfusions to survive, but chronic transfusions lead to unavoidable iron overload that can result in multi-organ damage and shortened life span.
“One-time treatment with LentiGlobin gene therapy resulted in positive outcomes for patients with TDT, with the majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer maintaining independence from transfusion without unexpected or unmanageable side effects,” said Dr. Alexis Thompson, Head of Hematology and Director of the Comprehensive Thalassemia Program at Ann & Robert H. Lurie Children’s Hospital of Chicago, and Professor of Pediatrics at Northwestern University Feinberg School of Medicine and one of the lead authors of the NEJM paper. “People with TDT cannot make enough hemoglobin in their red blood cells and rely on frequent transfusions to survive, which can cause serious complications. Most will not have a suitable donor for conventional allogeneic stem cell transplant. These results suggest that gene therapy could become an effective treatment for TDT.”
Interim Efficacy Results of the Northstar and HGB 205-Studies
The recently completed Northstar study (HGB-204) is an open-label, single-dose, non-randomized, multi-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin for the treatment of patients with TDT. HGB-205 is an ongoing, open-label, single-dose, non-randomized, single-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin for the treatment of patients with TDT and severe sickle cell disease (SCD).
Through June 2, 2017, 18 patients (ages 12 to 35) in the Northstar study, and four patients with TDT (ages 16 to 19) in HGB-205 had received LentiGlobin. Ten of the 18 patients in the Northstar study and three of the four patients in HGB-205 have non-β0/β0 genotypes. One patient in HGB-205 is homozygous for the IVS1-110 mutation and has a severe clinical presentation similar to that seen in β0/β0 genotypes. Interim results published in NEJM from all 22 patients with TDT in the two studies showed:
- At baseline, all 13 patients with non-β0/β0 genotypes were transfusion-dependent. With a median time since last transfusion of 27 months (range: 11-42 months), all but one of these 13 patients had stopped receiving regular RBC transfusions. These patients had a median level of gene therapy-derived hemoglobin (known as HbAT87Q) of 6.0 (3.4-10.0) g/dL and total hemoglobin of 11.2 (8.2-13.7) g/dL at the last study visit (12 to 36 months post-treatment).
- At baseline, all nine patients with genotypes that completely or nearly completely eliminate production of functional adult hemoglobin (β0/β0 genotypes or IVS1-110/IVS1-110 genotype) were transfusion-dependent. Three of these patients had stopped regular transfusions, with 14, 14 and 21 months having elapsed since their last transfusions, respectively. At the most recent study visit (12 to 30 months), these patients had 8.2, 6.8 and 6.6 g/dL HbAT87Q and 9.0, 10.2 and 8.3 g/dL total hemoglobin, respectively.
- The six remaining patients with β0/β0 genotypes continued to receive RBC transfusions; they had a median of 4.2 (0.3-8.7) g/dL HbAT87Q at last study visit. All but one of these patients had clinically meaningful reductions in the number and volume of transfusions compared with the two years prior to study enrollment.
Additionally, in the HGB-205 study, after the four patients with TDT ceased RBC transfusions following LentiGlobin therapy, the degree of hemolysis fully corrected in two patients by 36 months after treatment. After treatment with LentiGlobin, three patients with non-β0/β0 genotypes were able to transition to therapeutic phlebotomy (in which 200 ml of blood was withdrawn each month) to reduce the iron overload they had developed from chronic RBC transfusions. In these three patients, blood hemoglobin levels were stable despite a cumulative phlebotomy volume of over 1 liter per patient. One patient no longer had evidence of clinically meaningful iron overload and stopped receiving both iron chelation therapy and therapeutic phlebotomy.
Interim Safety Results of the Northstar and HGB 205-Studies
The safety profile of LentiGlobin in TDT continues to be consistent with myeloablative conditioning with the chemotherapy agent busulfan. In the Northstar study, five mild adverse events (AEs), all Grade 1, were characterized as possibly or probably related to LentiGlobin. Nine serious adverse events (SAEs) were reported, including two episodes of veno-occlusive liver disease; none were considered related to LentiGlobin. In HGB-205, there were three SAEs, all Grade 2 or 3. For both studies, all adverse events were treated with standard measures. There was no evidence of a single gene clone becoming dominant or of any patient developing a replication-competent strain of the viral vector. All patients who were engrafted survived.
About the Northstar (HGB-204) Study
The recently completed Phase 1/2 Northstar study is an open-label, single-dose, non-randomized, multi-center study conducted in the United States, Australia and Thailand. It was designed to evaluate the safety and efficacy of LentiGlobin in increasing hemoglobin production and eliminating or reducing transfusion dependence in subjects with transfusion dependent beta-thalassemia. The study treated 18 adults and adolescents who are being followed to evaluate safety and efficacy post-LentiGlobin infusion. For more information on the Northstar study, please visit www.northstarstudy.com or clinicaltrials.gov using identifier NCT01745120.
About the HGB-205 Study
The Phase 1/2 HGB-205 study is being conducted at a single site in France. It is designed to evaluate the safety and efficacy of LentiGlobin in the treatment of subjects with TDT and SCD. The study has enrolled seven subjects. Efficacy in subjects with TDT includes evaluation of transfusion requirements post-treatment and level of hemoglobin. For patients with SCD, efficacy is being measured based on the number of vaso-occlusive crises or acute chest syndrome events pre- and post-treatment. For more information on the HGB-205 study, please visit clinicaltrials.gov using identifier NCT02151526.
The principal investigator of the HGB-205 study is Marina Cavazzana, M.D., Ph.D., Professor of Hematology at Paris Descartes University, Director Biotherapy Department, Necker Hospital, AP-HP, and Co-director of the Human Lympho-hematopoiesis Inserm laboratory at Imagine Institute for Genetic Diseases, Paris, France, in collaboration with Philippe Leboulch, M.D., Professor of Medicine at the University Paris-Sud and High Counselor and Honorary Scientific Director at France’s Commissariat à l’énergie atomique et aux énergies alternatives (CEA) and visiting faculty at Harvard Medical School in the Genetics Division of Brigham & Women’s Hospital, Boston, MA. Dr. Leboulch was a scientific founder of bluebird bio and serves as the co-chairman of its Scientific Advisory Board.
Dr. Leboulch and his team led the development of the HbAT87Q LentiGlobin vector.
bluebird bio is developing LentiGlobin with a goal of filing for regulatory approval in the United States and the EU for TDT and for severe SCD. The company is currently conducting four ongoing clinical studies of LentiGlobin with a fifth that has recently completed. Studies currently ongoing include HGB-205, a single center Phase 1/2 study in both TDT and SCD; Northstar-2 (HGB-207) and Northstar-3 (HGB-212), both multi-center, international Phase 3 studies for the treatment of patients with both non-β0/β0 and β0/β0 TDT genotypes, respectively; and HGB-206, a multicenter Phase 1 study in the United States for the treatment of patients with severe SCD. In addition, bluebird is conducting a long-term safety and efficacy follow-up study (LTF-303) for subjects with hemoglobinopathies (TDT or severe SCD) who have been treated with LentiGlobin in bluebird bio-sponsored clinical studies.
LentiGlobin was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of β-thalassemia and SCD. The FDA granted Breakthrough Therapy designation to LentiGlobin for the treatment of transfusion-dependent patients with β-thalassemia major and Fast-Track Designation for the treatment of beta-thalassemia major and for the treatment of certain patients with severe SCD. bluebird bio is participating in the EMA’s Adaptive Pathways pilot program, which is part of the EMA’s effort to improve timely access for patients to new medicines. The EMA granted Priority Medicines (PRIME) eligibility to LentiGlobin for the treatment of TDT.
Transfusion-dependent β-thalassemia (TDT) is a severe genetic disease characterized by reduced or absent hemoglobin levels that results in severe anemia and ineffective red blood cell production. Supportive care for people with TDT consists of a lifelong regimen of chronic blood transfusions to enable survival and suppress symptoms of the disease, and iron chelation therapy to manage iron overload that results from the transfusions. Despite the availability of supportive care, many people with TDT experience serious complications and organ damage due to underlying disease and iron overload.
Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only available option to address the underlying genetic cause of TDT, though it carries significant risks. Complications of allogeneic HSCT include a risk of treatment-related mortality, graft failure, graft versus host disease (GvHD) and opportunistic infections, particularly in patients who undergo non-sibling matched allogeneic HSCT.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio's gene therapy clinical programs include its Lenti-D™ product candidate for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ product candidate for the treatment of transfusion-dependent β-thalassemia, also known as β-thalassemia major, and severe sickle cell disease. bluebird bio's oncology pipeline is built upon the company's leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio's lead oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs partnered with Celgene. bluebird bio also has discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington, Durham, North Carolina and Zug, Switzerland.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s research, development, manufacturing and regulatory approval plans for its LentiGlobin product candidate to treat transfusion-dependent ß-thalassemia and severe sickle cell disease. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials of LentiGlobin will not continue or be repeated in our ongoing or planned clinical trials of LentiGlobin, the risks that the changes we have made in the LentiGlobin manufacturing process or the HGB-206 clinical trial protocol will not result in improved patient outcomes, risks that the current or planned clinical trials of LentiGlobin will be insufficient to support regulatory submissions or marketing approval in the US and EU, and the risk that any one or more of our product candidates, including our bb2121 product candidate, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimilia Wins Expedia® Partner Solutions Account21.2.2019 11:00:00 | Pressemelding
Rimilia, a financial technology company, today announced that Expedia Partner Solutions (EPS), Expedia’s Business-to-Business partner network, selected Rimilia solutions to automate incoming payments. Rimilia will enable EPS to automate the application of their payments in 20 different currencies to open lodging supply/invoices from all of Expedia Group’s hotel, airline, car rental and holiday travel agency partners. Headquartered in Bellevue, Washington, Expedia Group is one of the world’s largest online travel companies with nearly $100 billion in gross bookings, $11 billion in revenue and 24,000 employees worldwide1. The Expedia Partner Solutions division supports thousands of travel partners with technology, travel supply and support services. Jeremy Hayes, Senior Manager for EAC Accounting at Expedia Partner Solutions, stated, “Our team manages cash and collection and applies payments from our travel partners all over the globe in multiple currencies. We have been looking for ways
emporia Showcases Four Products at Mobile World Congress21.2.2019 10:00:00 | Pressemelding
According to a 2018 emporia survey, 31 per cent of people over 65 and 50 per cent of 65 to 70-year-olds own a mobile phone with internet access. Meanwhile 85 per cent of smartphone users over the age of 65 use WhatsApp or other messenger services to stay in touch with friends and family. 59 per cent of grandchildren use WhatsApp to share their lives with grandparents. emporiaTOUCHsmart TOUCHsmart is a new clamshell smartphone from emporia. The combination of touch screen and physical keyboard is tailored to the needs of older generations. WhatsApp is pre-installed with a shortcut button, while emporia’s famous emergency system – which automatically calls up to five numbers at the touch of a button - instis a sense of security. emporiaSmart.3 The new Smart.3 smartphone has clear menu navigation in a stylish design. It features a 13 megapixel rear and 8 megapixel front camera and has a physical home button to make it simple to return to the main menu. The smartphone is splash proof and i
Toshiba Memory Corporation Develops New Bridge Chip Using PAM 4 to Boost SSD Speed and Capacity21.2.2019 09:52:00 | Pressemelding
Toshiba Memory Corporation, the world leader in memory solutions, today announced the development of a bridge chip that realizes high-speed and large-capacity SSDs. Using developed bridge chips with a small occupied area and low-power consumption, the company has succeeded in connecting more flash memory chips with fewer high-speed signal lines than with the conventional method of no bridge chips. This result was announced in San Francisco on February 20, at the International Solid-State Circuits Conference 2019 (ISSCC 2019). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005378/en/ Fig. 1 Connection using bridge chips (Graphic: Business Wire) In SSDs, multiple flash memory chips are connected to a controller that manages their operation. As more flash memory chips are connected to a controller interface, operating speed degrades, so there are limits to the number of chips that can be connected. In order to increase ca
GSMA: Low Power Mobile IoT Networks Now Available from All Leading IoT Operators Worldwide21.2.2019 09:00:00 | Pressemelding
The GSMA today announced that Mobile IoT or Low Power Wide Area (LPWA) networks are now globally available in licensed spectrum in 49 markets1 around the world following 93 launches by 50 different mobile operators across both LTE-M and NB-IoT. Coverage is now expected to reach approximately 93% of the world’s largest IoT markets by Q2 20192. According to GSMA Intelligence forecasts, by 2025 there will be 3.5 billion cellular IoT connections, including 1.9 billion licensed LPWA connections3. “The speed with which these networks have been standardized and deployed around the world is staggering. They are now available in every major IoT market encouraging the development of innovative new products and services across a wide range of sectors,” commented Alex Sinclair, Chief Technology Officer, GSMA. “The market clearly sees the benefit of solutions in licensed spectrum that offer flexibility, adaptability, security and lower cost. They are also future proofed for the 5G era and will supp
Meggitt Training Systems to Highlight Expanded Virtual and Live-Fire Solutions at IWA Outdoor Classics21.2.2019 09:00:00 | Pressemelding
With two European facilities to serve shooting range customers across the continent, Meggitt Training Systems will feature the latest virtual and live-fire products March 8-11, 2019, at IWA Outdoor Classics (stand #3-211) in Nuremberg, Germany. A leader for more than nine decades in the design, equipment and installation for law enforcement, defense and commercial ranges, Meggitt Training Systems has fielded more than 13,000 range systems worldwide, including over 75,000 live-fire target systems on 122 military bases. “Meggitt understands and serves Europe’s unique live-fire training requirements thanks in part to our regional facilities in Ashford and Waardenburg,” said Mark Mears, managing director for Meggitt Training Systems Ltd. “IWA Outdoor Classics attendees are welcome to see how our unrivalled expertise can facilitate the design and construction of new and upgraded shooting ranges.” Meggitt’s display of products at IWA will include: The XWT ProImage® projected target system re
New GSMA Report Highlights Global Role of Intelligent Connectivity21.2.2019 09:00:00 | Pressemelding
The GSMA today issued a new report, ‘Intelligent Connectivity: How the Combination of 5G, AI, Big Data and IoT Is Set to Change Everything ,’ highlighting how 5G networks, artificial intelligence (AI), smart platforms and the Internet of Things (IoT) is set to transform the lives of citizens and businesses around the world. The in-depth report draws on fresh interviews with senior representatives from Deutsche Telekom, GSMA Intelligence, KT Corp, Telefonica and Vodafone and outlines how the convergence of computing and communications will drive a step-change in productivity by delivering real-time services across multiple sectors such as entertainment, transportation and manufacturing. GSMA Intelligence estimates that there will be 1.4 billion global 5G connections by 2025 accounting for more than 15 per cent of the mobile market. “The combination of 5G, the IoT, Big Data and AI will impact almost every aspect of our daily lives from the way we consume entertainment to the way in which